Retinopathy risk factors in patients with type 2 diabetes on liraglutide.

Mahzari MM, Alanazy AM, Feroz Z, Almani KM, Alghamdi MA, Almadani AS, Alzahrani MK, Alibrahim AR, Badri M

Medicine1 Jul 2024Cited by 3 (Europe PMC)

PMID39029073PMCIDPMC11398743DOI10.1097/md.0000000000039026PepBankPUB-39029073

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study10

5 results from studies that gave the peptide. 5 results from people.

01HumanObservational studyEfficacy outcome
In adults with type 2 diabetes, HbA1c decreased significantly during a median of 2 years of liraglutide use.
In plain wordsIn adults with type 2 diabetes, HbA1c fell during about 2 years of liraglutide use. The study had no comparison group.
Peptide
Liraglutide
Outcome
DecreaseHbA1c change
Study
n = 181
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · median 2 yearsAs given in this study (human).
Source sentences
Summary
After a median of 2 years follow-up, both HbA1c level and weight decreased significantly (P < .001).
1 context sentence(design, population, supporting numbers)
Summary · context
This retrospective cohort study was conducted on patients (≥14 years) with T2D treated with liraglutide between 2015 and 2021, who had a documented retinopathy assessment at baseline before liraglutide initiation and during follow-up, at King Abdulaziz Medical City (KAMC), Riyadh.
Report a problemFND-3902907301
02HumanObservational studyEfficacy outcome
In adults with type 2 diabetes, body weight decreased significantly during a median of 2 years of liraglutide use.
In plain wordsIn adults with type 2 diabetes, body weight fell during about 2 years of liraglutide use. The study had no comparison group.
Peptide
Liraglutide
Outcome
DecreaseBody weight change
Study
n = 181
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · median 2 yearsAs given in this study (human).
Source sentences
Summary
After a median of 2 years follow-up, both HbA1c level and weight decreased significantly (P < .001).
1 context sentence(design, population, supporting numbers)
Summary · context
This retrospective cohort study was conducted on patients (≥14 years) with T2D treated with liraglutide between 2015 and 2021, who had a documented retinopathy assessment at baseline before liraglutide initiation and during follow-up, at King Abdulaziz Medical City (KAMC), Riyadh.
Report a problemFND-3902907302
03HumanObservational studySafety outcome
In adults with type 2 diabetes and no retinopathy at baseline, 81.6% of the 87 patients still had no retinopathy after liraglutide use.
In plain wordsIn adults with type 2 diabetes and no eye disease at the start, most still had none after liraglutide use.
Peptide
Liraglutide
Outcome
No significant changeRetinopathy status in patients without baseline retinopathy
Study
n = 87
Outcome group
Vision and retina · Eye
Studied dose
Dose not stated · median 2 yearsAs given in this study (human).
Measurements
Proportion with no retinopathy
81.6%
no retinopathy at baseline
Source sentences
Summary
Seventy-one of the 87 patients (81.6%) without retinopathy at baseline continued to show no retinopathy.
1 context sentence(design, population, supporting numbers)
Summary · context
This retrospective cohort study was conducted on patients (≥14 years) with T2D treated with liraglutide between 2015 and 2021, who had a documented retinopathy assessment at baseline before liraglutide initiation and during follow-up, at King Abdulaziz Medical City (KAMC), Riyadh.
Report a problemFND-3902907303
04HumanObservational studyEfficacy outcome
In adults with type 2 diabetes and retinopathy at baseline, 25.5% showed improvement after liraglutide use.
In plain wordsIn adults with type 2 diabetes and existing eye disease, about one in four showed improvement after liraglutide use. The study had no comparison group.
Peptide
Liraglutide
Outcome
DecreaseRetinopathy improvement in patients with baseline retinopathy
Study
n: not reported in source
Outcome group
Vision and retina · Eye
Studied dose
Dose not stated · median 2 yearsAs given in this study (human).
Measurements
Patients with improved retinopathy
25.5%
retinopathy at baseline
Source sentences
Summary
Among patients with retinopathy at baseline, 25.5% showed improvement and 44.7% showed no change.
1 context sentence(design, population, supporting numbers)
Summary · context
This retrospective cohort study was conducted on patients (≥14 years) with T2D treated with liraglutide between 2015 and 2021, who had a documented retinopathy assessment at baseline before liraglutide initiation and during follow-up, at King Abdulaziz Medical City (KAMC), Riyadh.
Report a problemFND-3902907304
05HumanObservational studyEfficacy outcome
In adults with type 2 diabetes and retinopathy at baseline, 44.7% showed no change after liraglutide use.
In plain wordsIn adults with type 2 diabetes and existing eye disease, 44.7% showed no change after liraglutide use.
Peptide
Liraglutide
Outcome
No significant changeRetinopathy unchanged in patients with baseline retinopathy
Study
n: not reported in source
Outcome group
Vision and retina · Eye
Studied dose
Dose not stated · median 2 yearsAs given in this study (human).
Measurements
Patients with unchanged retinopathy
44.7%
retinopathy at baseline
Source sentences
Summary
Among patients with retinopathy at baseline, 25.5% showed improvement and 44.7% showed no change.
1 context sentence(design, population, supporting numbers)
Summary · context
This retrospective cohort study was conducted on patients (≥14 years) with T2D treated with liraglutide between 2015 and 2021, who had a documented retinopathy assessment at baseline before liraglutide initiation and during follow-up, at King Abdulaziz Medical City (KAMC), Riyadh.
Report a problemFND-3902907305

Studies that did not test the peptide alone5

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

06HumanNot a test of Liraglutide aloneObservational studyOther
In adults with type 2 diabetes treated with liraglutide, insulin use was significantly associated with retinopathy.
In plain wordsIn adults with type 2 diabetes treated with liraglutide, insulin use was linked to retinopathy.
Peptide
Liraglutide
Outcome
Not applicableInsulin use as a risk factor for retinopathy
Study
n: not reported in source
Outcome group
Vision and retina · Eye
Measurements
Odds ratio
2.68 ratio
use of insulin
Source sentences
Summary
use of insulin (odds ratio [OR]:2.68; 95% confidence interval [CI]: 1.18-6.09, P = .019)
1 context sentence(design, population, supporting numbers)
Summary · context
This retrospective cohort study was conducted on patients (≥14 years) with T2D treated with liraglutide between 2015 and 2021, who had a documented retinopathy assessment at baseline before liraglutide initiation and during follow-up, at King Abdulaziz Medical City (KAMC), Riyadh.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3902907306
07HumanNot a test of Liraglutide aloneObservational studyOther
In adults with type 2 diabetes treated with liraglutide, older age was significantly associated with retinopathy.
In plain wordsIn adults with type 2 diabetes treated with liraglutide, older age was linked to retinopathy.
Peptide
Liraglutide
Outcome
Not applicableOlder age as a risk factor for retinopathy
Study
n: not reported in source
Outcome group
Vision and retina · Eye
Measurements
Odds ratio
1.03 ratio
older age
Source sentences
Summary
older age (OR:1.03; 95% CI: 1.00-1.06; P = .022)
1 context sentence(design, population, supporting numbers)
Summary · context
This retrospective cohort study was conducted on patients (≥14 years) with T2D treated with liraglutide between 2015 and 2021, who had a documented retinopathy assessment at baseline before liraglutide initiation and during follow-up, at King Abdulaziz Medical City (KAMC), Riyadh.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3902907307
08HumanNot a test of Liraglutide aloneObservational studyOther
In adults with type 2 diabetes treated with liraglutide, a higher HbA1c level was significantly associated with retinopathy.
In plain wordsIn adults with type 2 diabetes treated with liraglutide, higher HbA1c was linked to retinopathy.
Peptide
Liraglutide
Outcome
Not applicableHigher HbA1c as a risk factor for retinopathy
Study
n: not reported in source
Outcome group
Vision and retina · Eye
Measurements
Odds ratio
1.17 ratio
higher HbA1c level
Source sentences
Summary
higher HbA1c level (OR:1.17; 95% CI: 1.02-1.34; P = .024)
1 context sentence(design, population, supporting numbers)
Summary · context
This retrospective cohort study was conducted on patients (≥14 years) with T2D treated with liraglutide between 2015 and 2021, who had a documented retinopathy assessment at baseline before liraglutide initiation and during follow-up, at King Abdulaziz Medical City (KAMC), Riyadh.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3902907308
09HumanNot a test of Liraglutide aloneObservational studyOther
In adults with type 2 diabetes treated with liraglutide, hypertension was significantly associated with retinopathy.
In plain wordsIn adults with type 2 diabetes treated with liraglutide, hypertension was linked to retinopathy.
Peptide
Liraglutide
Outcome
Not applicableHypertension as a risk factor for retinopathy
Study
n: not reported in source
Outcome group
Vision and retina · Eye
Measurements
Odds ratio
2.56 ratio
hypertension
Source sentences
Summary
Hypertension (OR:2.56; 95% CI: 1.13-5.76; P=<.0001)
1 context sentence(design, population, supporting numbers)
Summary · context
This retrospective cohort study was conducted on patients (≥14 years) with T2D treated with liraglutide between 2015 and 2021, who had a documented retinopathy assessment at baseline before liraglutide initiation and during follow-up, at King Abdulaziz Medical City (KAMC), Riyadh.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3902907309
10HumanNot a test of Liraglutide aloneObservational studyOther
In adults with type 2 diabetes treated with liraglutide, longer diabetes duration was significantly associated with retinopathy.
In plain wordsIn adults with type 2 diabetes treated with liraglutide, longer time with diabetes was linked to retinopathy.
Peptide
Liraglutide
Outcome
Not applicableLonger diabetes duration as a risk factor for retinopathy
Study
n: not reported in source
Outcome group
Vision and retina · Eye
Measurements
Odds ratio
1.04 ratio
longer diabetes duration
Source sentences
Summary
longer diabetes duration (OR:1.04; 95% CI: 1.00-1.08; P = .024).
1 context sentence(design, population, supporting numbers)
Summary · context
This retrospective cohort study was conducted on patients (≥14 years) with T2D treated with liraglutide between 2015 and 2021, who had a documented retinopathy assessment at baseline before liraglutide initiation and during follow-up, at King Abdulaziz Medical City (KAMC), Riyadh.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3902907310

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.